Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $153.76 USD
Change Today -2.04 / -1.31%
Volume 1.9M
EW On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp. to Report Q2, 2015 Results on Jul 28, 2015

Edwards Lifesciences Corp. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 28, 2015

Edwards Lifesciences Corp., Q2 2015 Earnings Call, Jul 28, 2015

Edwards Lifesciences Corp., Q2 2015 Earnings Call, Jul 28, 2015

Edwards Lifesciences Corp. Presents at Piper Jaffray Heartland Summit, Jun-23-2015

Edwards Lifesciences Corp. Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Michael A. Mussallem, Chairman and Chief Executive Officer.

Edwards Receives FDA Approval for Sapien 3 Transcatheter Heart Valve

Edwards Lifesciences Corporation announced U.S. Food and Drug Administration (FDA) approval of its most advanced transcatheter aortic heart valve the Edwards SAPIEN 3 valve with the Commander Delivery System for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. The PARTNER II study concluded that this new valve reduced several complications associated with the TAVR procedure such as paravalvular leakage and stroke, and represented a meaningful improvement over data from prior studies with earlier-generation devices. SAPIEN 3 approval was based on a cohort of the PARTNER II Trial, which enrolled 583 high-risk patients at 29 U.S. sites. The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve, available in 20mm, 23mm, 26mm and 29mm sizes, has an outer skirt a cuff of fabric surrounding the valve frame providing a seal to address paravalvular leak.

Edwards Lifesciences Corporation Announces Encouraging Results from Aortic Stenosis Study

Edwards Lifesciences Corporation has announced that patients with aortic stenosis who received Edwards SAPIEN 3 transcatheter aortic valve via transfemoral delivery had a one-year survival rate of 91.6%, as well as low rates of stroke and paravalvular leak. The independently adjudicated data from the CE Mark study were presented. Among the outcomes reported from the study, transfemoral SAPIEN 3 transcatheter aortic valve replacement (TAVR) was associated with a disabling stroke rate of 1.1%. In addition, only 2% of patients had moderate paravalvular leaks and there were no reports of severe leaks. There were also no observations of structural valve deterioration. "The one-year survival rate in the transfemoral cohort is the high reported in a multicenter, fully adjudicated TAVR study to date. These results set a new standard of care for patients at high risk for surgical aortic valve replacement. The results of the SAPIEN 3 trial via the transfemoral approach also raise the question of whether transcatheter valve replacement should be considered for approval for all elderly patients with severe aortic stenosis’. The SAPIEN 3 Trial is a prospective, multicenter, non-randomized study. The one-year analysis documented outcomes of the first 150 patients treated with the SAPIEN 3 valve between Jan. 2013 and Nov. 2013 at 16 centers in Europe and Canada. Access approaches included transfemoral (n=96) and transapical/transaortic (n=54), as determined by the Heart Team. At baseline, the patients in the alternative access group were significantly sicker than the transfemoral group. All-cause mortality in the alternative access group was reported as 24.3% in the as-treated population. The SAPIEN 3 Trial is designed to evaluate patients annually for five years. The SAPIEN 3 valve can be delivered through a low-profile 14 French expandable sheath (eSheath). It also has an outer skirt - a cuff of fabric that provides a seal at the bottom of the frame that is designed to reduce paravalvular aortic regurgitation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $153.76 USD -2.04

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $194.55 USD +1.60
Endo International PLC $86.19 USD -1.44
Hologic Inc $38.03 USD +0.49
Intuitive Surgical Inc $540.29 USD +0.03
Mettler-Toledo International Inc $337.75 USD +2.76
View Industry Companies
 

Industry Analysis

EW

Industry Average

Valuation EW Industry Range
Price/Earnings 38.8x
Price/Sales 6.9x
Price/Book 7.3x
Price/Cash Flow 38.1x
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.